Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 15/20 | 0.84 |
| ▸ | WDR77 | Q9BQA1 | 14/20 | 0.84 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | AHCY | P23526 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23294331 | 1.00 | PRMT5 (0.84) | PRMT5WDR77ADORA1ADORA3AHCY | |
| SCHEMBL29705956 | 1.00 | PRMT5 (0.84) | PRMT5WDR77ADORA1ADORA3AHCY | |
| SCHEMBL22509067 | 0.93 | PRMT5 (0.84) | PRMT5WDR77ADORA1ADORA3 | |
| SCHEMBL29706001 | 0.93 | PRMT5 (0.84) | PRMT5WDR77ADORA1ADORA3 | |
| SCHEMBL23294566 | 0.93 | PRMT5 (0.84) | PRMT5WDR77ADORA1ADORA3 | |
| SCHEMBL22501904 | 0.92 | PRMT5 (1.00) | PRMT5WDR77ADORA1AHCY | |
| SCHEMBL22509048 | 0.92 | PRMT5 (0.76) | PRMT5WDR77ADORA1ADORA3AHCY | |
| SCHEMBL23294215 | 0.92 | PRMT5 (0.76) | PRMT5WDR77ADORA1ADORA3AHCY | |
| SCHEMBL22501903 | 0.92 | PRMT5 (1.00) | PRMT5WDR77ADORA1AHCY | |
| SCHEMBL29705817 | 0.92 | PRMT5 (0.76) | PRMT5WDR77ADORA1ADORA3AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | disclosed |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | disclosed |
| US-11220524-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-01-11 | — | — | US | disclosed |
| US-11220524-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210130388-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2021-05-06 | — | — | US | disclosed |
| US-20210130388-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2021-05-06 | — | — | US | disclosed |
| WO-2020206308-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130388-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885WDR77 59/4885ADORA1 4563/4885 |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885WDR77 52/4885ADORA1 4710/4885 |
| US-11220524-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885WDR77 59/4885ADORA1 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.